AHC has an estimated prevalence of 1/1 000 000 children, and 75% of clinically diagnosed cases are due to de novo mutations in the ATP1A3 gene, most commonly, the D801N mutation.7 This evidence concerns the gene ATP1A3 and alternating hemiplegia of childhood.